Guardian Bio
Dendritic cell-based platform for cancer therapy
Guardian Bio at a glance
- Y Combinator batch
- Summer 2022
- Status
- Active
- Industry
- Healthcare
- Team size
- 2 people
- Location
- Not recorded
- Website
- Not recorded
Every field above comes from the Y Combinator company record. Nothing is estimated.
About Guardian Bio
Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. Our therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.